CTOs on the Move

Unigene Laboratories

www.unigene.com

 
Unigene Laboratories, Inc. (Unigene) is a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has a manufacturing technology for producing many peptides
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.unigene.com
  • 110 Little Falls Rd
    Fairfield, NJ USA 07004
  • Phone: 973.265.1100

Executives

Name Title Contact Details

Similar Companies

AmacaThera

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Highmark Delaware

Highmark Delaware is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Talaris Therapeutics

Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.

iCyt Mission Technology

iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onconova

Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.